Navigation Links
Watson Announces Positive Data for Its New Investigational Products for Benign Prostatic Hyperplasia and Overactive Bladder
Date:5/21/2008

ese factors include, among others, the impact of competitive products and pricing; market acceptance of and continued demand for Watson's products; difficulties or delays in manufacturing; and other risks and uncertainties detailed in Watson's periodic public filings with the Securities and Exchange Commission, including but not limited to Watson's Annual Report on Form 10-K for the year ended December 31, 2007.

MIXJECT(R) is manufactured by and is a registered trademark of Medimop Medical Projects Ltd., a subsidiary of West Pharmaceutical Services, Inc., and is manufactured by West Pharmaceutical Services, Inc.

(Logo: http://www.newscom.com/cgi-bin/prnh/20080521/LAW511)


'/>"/>
SOURCE Watson Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6

Related medicine technology :

1. Watson Announces Silodosin NDA Accepted for Filing by FDA for the Treatment of Benign Prostatic Hyperplasia
2. Watson Announces Positive Results From Its Pivotal Study of Oxybutynin Topical Gel for the Treatment of Overactive Bladder
3. Watson Launches Generic Biaxin(R) XL
4. QuatRx Pharmaceuticals Announces Presentation of Further Data from Ophena(TM) (Ospemifene) Phase 3 Study for Treatment of Symptoms of Vulvovaginal Atrophy
5. Alba Therapeutics Announces the Presentation of Results of a Phase IIa Clinical Trial for Larazotide Acetate for the Treatment of Celiac Disease at the Digestive Disease Week Conference
6. PTC Therapeutics Announces Data Supporting Cough Frequency as a New Outcome Measure in Evaluating Treatments for Cystic Fibrosis
7. Telik Announces Initiation of Two Phase 2 Randomized TELINTRA Studies
8. Omeros Announces Initiation of Patient Enrollment in OMS201 Phase 1 Study
9. Fuisz Tobacco Announces Clinical Study Results for Fuisz Tobacco Sheet Strip; Super Enhanced Bioavailability of Nicotine From Its Tobacco Sheet Strip Supports Efficacy of Low Dose Tobacco Product
10. InterMune Announces Receipt of Fast Track Designation for Pirfenidone From FDA
11. Ipsogen Announces Three Studies at the American Society of Clinical Oncology (ASCO) Meeting Extending the Utility of the Genomic Grade Index for Predicting Response to Chemotherapy in Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/1/2008).... 1 Vical Incorporated (...$1.0 million milestone payment from Merck & Co...hase I clinical trial of an investigational plasmi... is based on Vical,s DNA gene delivery technology ... (hTERT). hTERT is the subject of separate license...
(Date:11/28/2008)...Nov. 28 Eli Lilly and Co...al New Drug Application (sNDA) from,the U.S. Food...loxetine HCl),for the management of chronic pain....irst half of 2009, adding data from a recently com...ain of the knee. , The decision does not af...
(Date:11/26/2008)... to 406 Subjects , , FRANKLIN, Mass., Nov. ... Bulletin Board: PLCSF) announced today that it ha...ug Administration (FDA) for its U.S. pivotal trial...Guard System(TM) and associated therapy in the pr... , The FDA also approved PLC,s request to ex...
(Date:11/25/2008)...CISCO, Calif., Nov. 25 Proteolix, ...f novel therapeutics that target,protein degradat...day,announced that data from two ongoing Phase 2 ...a will be presented at the upcoming 50th Annual Me.... Carfilzomib is the first in a new class,of spe...
Breaking Medicine Technology:Vical Receives Milestone Payment from Merck & Co., Inc. Triggered by Planned Initiation of Investigational Cancer DNA Vaccine Trial 2Lilly Withdraws Application for Additional U.S. Indication for Cymbalta(R) for Chronic Pain 2Lilly Withdraws Application for Additional U.S. Indication for Cymbalta(R) for Chronic Pain 3Lilly Withdraws Application for Additional U.S. Indication for Cymbalta(R) for Chronic Pain 4PLC Systems Receives Full FDA Approval for Pivotal Study of RenalGuard(TM) in The U.S. 2PLC Systems Receives Full FDA Approval for Pivotal Study of RenalGuard(TM) in The U.S. 3PLC Systems Receives Full FDA Approval for Pivotal Study of RenalGuard(TM) in The U.S. 4Proteolix to Present Clinical and Preclinical Data at the 50th Annual Meeting of the American Society of Hematology 2Proteolix to Present Clinical and Preclinical Data at the 50th Annual Meeting of the American Society of Hematology 3Longs Drugs Partners With Google on the Launch of Google Health 19817 1Longs Drugs Partners With Google on the Launch of Google Health 19817 2bioMETRX Expands Engineering and Manufacturing Capabilities 3366 1bioMETRX Expands Engineering and Manufacturing Capabilities 3366 2bioMETRX Expands Engineering and Manufacturing Capabilities 3366 3TAK 390MR Phase 3 data presented at Digestive Disease Week 19814 1TAK 390MR Phase 3 data presented at Digestive Disease Week 19814 2TAK 390MR Phase 3 data presented at Digestive Disease Week 19814 3TAK 390MR Phase 3 data presented at Digestive Disease Week 19814 4Greener offices make happier employees 19812 1Greener offices make happier employees 19812 2
...wswire-FirstCall/ --,Nuvelo, Inc. today announced ...n with rNAPc2 To Help Eliminate MACE)/TIMI 32 Phas...ulant protein c2,(rNAPc2) in patients with non-ST-... be presented in a V-poster presentation at the of...aking place in New,Orleans, LA, March 24-27, 2007....
...the American College of Cardiology,s Scientific,Se...Inc. (NASDAQ: AGIX) today,announced that its ARISE...te, AGI-1067, did not show a difference from place...did achieve a number of,other important predefined...n the composite of "hard" atherosclerotic clinical...
Other Medicine Technology:Nuvelo Announces Presentation on rNAPc2 at American College of,Cardiology 56th Annual Scientific Session 2Nuvelo Announces Presentation on rNAPc2 at American College of,Cardiology 56th Annual Scientific Session 3AtheroGenics Reports ARISE Trial Results for AGI-1067 2AtheroGenics Reports ARISE Trial Results for AGI-1067 3AtheroGenics Reports ARISE Trial Results for AGI-1067 4
(Date:12/2/2008)... Marathon Health, a leading pro...utions, has announced that New Balance, the athlet...to develop, implement and manage onsite health cli...New Balance facilities in Maine , ...- Marathon Health, a leading provider of onsite em...
(Date:12/2/2008)... For many families, the problem...sther Koch provides insight into how caregivers of...ason to the elder care experience. , ... -- For many families the stress of the holiday se...logist and elder care expert Esther Koch , founde...
(Date:12/2/2008)... National Non-profit Launches A...vides Eye Exams at No Cost to Eligible Patients an... San Francisco, CA (Vocus) December 2, 2008 -...ho suffer with an eye disease known as Age-related..."No.", , , , ,Picture this…. a l...
(Date:12/2/2008)... Orion Health announces that th...RHC) of Juneau, Alaska, has selected the Rhapsody&...ectronic health record, radiology, pharmacy, labor...other. It also plans to extend connectivity to sta...a immunization registry) and AKAIMS (an MIS and cl...
Breaking Medicine News(10 mins):Health News:Marathon Health Joins Forces with New Balance for Employee Health - Associate Health Services Provided at Three Maine Locations 2Health News:Marathon Health Joins Forces with New Balance for Employee Health - Associate Health Services Provided at Three Maine Locations 3Health News:Holidays with Aging Parents: Elder Care Expert Has the Prescription for Caregiver Stress 2Health News:Holidays with Aging Parents: Elder Care Expert Has the Prescription for Caregiver Stress 3Health News:This Holiday Season EyeCare America Asks Seniors, 'Do you see what I see?' 2Health News:This Holiday Season EyeCare America Asks Seniors, 'Do you see what I see?' 3Health News:SouthEast Alaska Regional Health Consortium Selects Orion Health's Rhapsody Integration Engine for Full-scale Application Integration and Monitoring 2Health News:SouthEast Alaska Regional Health Consortium Selects Orion Health's Rhapsody Integration Engine for Full-scale Application Integration and Monitoring 3
...as been impersonating as a licensed medical practi...ants, providing them with false certificates and m...ter his guilt was established, according o the pro...out any license, hood winked immigrants by injecti...
...y agenda is to transfer water from the Missouri Ri...pulated areas in the red river drainage basin. // ...his proposition, due to a perceptible risk of fore...ce Olivastri, executive director of Friends of the...
...nd his colleagues found that hormonal changes play...rder) after girls begin menstruation. // The par...he age group of 13- to 16 years old. It was surpri...ffer from insomnia. Insomnia can be clinically def...
...ive of choice. They seem to be partial to middle a...urosurgery and Psychiatry suggests that // Family ...s to middle aged women with headache as compared t...lly spur the patients to a doctor and account for ...
Other Medicine News:
...UP Laboratories is a national reference laboratory...esearch and development. ARUP offers an extensive ...ts in clinical and anatomic pathology. Owned by th...nclude more than half of the nation's university t...
...UP Laboratories is a national reference laboratory...esearch and development. ARUP offers an extensive ...ts in clinical and anatomic pathology. Owned by th...nclude more than half of the nation's university t...
...UP Laboratories is a national reference laboratory...esearch and development. ARUP offers an extensive ...ts in clinical and anatomic pathology. Owned by th...nclude more than half of the nation's university t...
...UP Laboratories is a national reference laboratory...esearch and development. ARUP offers an extensive ...ts in clinical and anatomic pathology. Owned by th...nclude more than half of the nation's university t...
Medicine Products: